Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Castellano

Showing results (241-250 of 266) with videos related to

Pageof 27
Sort By:
Cell Reports. Medicine|June 23, 2026
Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO studyEnrique Grande, Mustafa Sibai, Daniela Grases, et al.
The Prostate|December 24, 2022
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamideMaría P Fernandez-Perez, Enrique Perez-Navarro, Teresa Alonso-Gordoa, et al.
Clinical Genitourinary Cancer|January 11, 2025
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial CarcinomaRafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al.
Urologic Oncology|April 8, 2017
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicityLoes F M van der Zanden, Sita H Vermeulen, Arna Oskarsdottir, et al.
Clinical Genitourinary Cancer|July 6, 2023
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" ExperienceDimitra Rafailia Bakaloudi, Rafee Talukder, Genevieve Ihsiu Lin, et al.
Cancers|July 27, 2024
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate CancerEnrique Perez-Navarro, Vincenza Conteduca, Juan M Funes, et al.
Cancer Treatment Reviews|January 15, 2017
Strategies to design clinical studies to identify predictive biomarkers in cancer researchJose Luis Perez-Gracia, Miguel F Sanmamed, Ana Bosch, et al.
Clinical Genitourinary Cancer|September 6, 2024
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint InhibitorDimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, et al.
Lancet (London, England)|September 17, 2017
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialDaniel P Petrylak, Ronald de Wit, Kim N Chi, et al.
BMC Cancer|February 25, 2016
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 studyNuria Lainez, Jesús García-Donas, Emilio Esteban, et al.
Pageof 27

Showing results (241-250 of 266) with videos related to

Sort By:
Pageof 27
Cell Reports. Medicine|June 23, 2026
Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO studyEnrique Grande, Mustafa Sibai, Daniela Grases, et al.
The Prostate|December 24, 2022
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamideMaría P Fernandez-Perez, Enrique Perez-Navarro, Teresa Alonso-Gordoa, et al.
Clinical Genitourinary Cancer|January 11, 2025
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial CarcinomaRafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al.
Urologic Oncology|April 8, 2017
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicityLoes F M van der Zanden, Sita H Vermeulen, Arna Oskarsdottir, et al.
Clinical Genitourinary Cancer|July 6, 2023
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" ExperienceDimitra Rafailia Bakaloudi, Rafee Talukder, Genevieve Ihsiu Lin, et al.
Cancers|July 27, 2024
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate CancerEnrique Perez-Navarro, Vincenza Conteduca, Juan M Funes, et al.
Cancer Treatment Reviews|January 15, 2017
Strategies to design clinical studies to identify predictive biomarkers in cancer researchJose Luis Perez-Gracia, Miguel F Sanmamed, Ana Bosch, et al.
Clinical Genitourinary Cancer|September 6, 2024
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint InhibitorDimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, et al.
Lancet (London, England)|September 17, 2017
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialDaniel P Petrylak, Ronald de Wit, Kim N Chi, et al.
BMC Cancer|February 25, 2016
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 studyNuria Lainez, Jesús García-Donas, Emilio Esteban, et al.
Pageof 27